[Lani]

“Unusual three-drug combo inhibits growth of aggressive tumors”

“An experimental anti-cancer regimen combined a diuretic, a Parkinson’s disease medication and a drug ordinarily used to reverse the effect of sedatives. The unusual mixture inhibited the growth of aggressive prostate tumors in laboartory mice in research conducted at Washington University School of Medicine in St. Louis.

Although their drug choices may seem capricious, the researchers weren’t randomy pulling drugs from their shelves. They made their discovery using sophisticated methods for delving into the unique metabolism of cancer cells and then choosing compounds likely to interfere with their growth.

‘This study, led by Joseph Ippolito, a very talented M.D./Ph.D. student, demonstrates the importance of looking at tumor metabolism,’ says senior author Jeffrey I. Gordon, M.D., director of the Center for Genome Sciences at the School of Medicine. ‘Using a broad array of technology, we’ve obtained a view of the tumor cells’ metabolome (the set of small-molecule metabolites found within cells) and revealed aspects that were not expected and could be exploited.’

The findings, published in a recent article in the Proceedings of the National Academy of Sciences, expand upon earlier work by the research group, which demonstrated that aggressive types of neuroendocrine tumors - seen in some types of lung, thyroid and prostate cancers - produce high amounts of a chemical called GABA, a neurotransmitter.

Because of the abundance of GABA in these tumors, the authors previously proposed that the chemical could potentially serve as a marker for poor-prognosis neuroendocrine tumors. But the latest findings also show that the techniques used to decipher the biochemistry of the tumors can effectively be applied to seek drugs that will affect tumor metabolism.

The techniques link DNA microarray technology - which can pinpoint highly active genes in the tumors - to precise measurements of abundant metabolites and their potential byproducts within intact tumor cells using nuclear magnetic resonance (nMR) spectroscopy and mass spectometry. Software programs take this information and provide testable predictions about how these substances might drive the special metabolism of cancerous cells.

Investigating experimental mice that develop metastatic tumors of the prostate’s neuroendocrine cells, the researchers discovered that the tumor cells relied on molecules that transmit signals betweeen neurons. They found that the tumor cellls respond to GABA as well as to two other neurotransmiitters, glycine and glutamate.

‘The question was, “What are these neural signaling molecules doing in tumor cells found outside the central nervous system?”’ says lead author Joseph E. Ippolito.

The reserachers demonstrated that the tumor cells have receptors on their surface that recognize these neurotransmtters and are activated by them. In addition, the tumor cells